Literature DB >> 2670208

Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review.

S A Rosenberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2670208     DOI： 10.1016/0305-7372(89)90031-5

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  13 in total

1.  Molecular Events as Targets of Anticancer Drug Therapy.

Authors:  Adorján Aszalós; Sándor Eckhardt
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 2.  Immunomodulators. Future prospects.

Authors:  B C Takx-Köhlen
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 3.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

4.  Renal effects of continuous infusion of recombinant interleukin-2 in children.

Authors:  P Cochat; D Floret; E Bouffet; C R Francks; M C Favrot; T Philip; L David
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

Review 5.  Interleukin-2 and interferon in renal cell carcinoma.

Authors:  P Wersäll
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 6.  Role of interleukin-2 in human hematological malignancies.

Authors:  A Toren; A Ackerstein; S Slavin; A Nagler
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

Review 7.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

8.  Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha.

Authors:  W M Vuist; M J Visseren; M Otsen; K Bos; F A Vyth-Dreese; C G Figdor; C J Melief; A Hekman
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

9.  Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.

Authors:  Y F Zhai; W J Esselman; C S Oakley; C C Chang; C W Welsch
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Antitumor effects of oral administration of an interferon-inducing pyrimidinone, Bropirimine, on murine renal-cell carcinoma.

Authors:  T Fujioka; K Ishikura; M Hasegawa; K Ogyu; Y Matsushita; M Sato; F Sato; H Aoki; T Kubo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.